Skip to main content
. Author manuscript; available in PMC: 2024 Jan 29.
Published in final edited form as: J Thromb Haemost. 2023 Apr 15;21(8):2236–2247. doi: 10.1016/j.jtha.2023.04.008

Figure 4:

Figure 4:

Role of platelet PAR4 and GPVI in TEG. Blood samples were analyzed from WT mice (n=8), mice with megakaryocyte/platelet-specific deletion of PAR4 (PAR4mKO, n=5), WT mice treated with anti-GPVI antibody to deplete GPVI on circulating platelets (JAQ1, 50 μg/mouse, n=4), or JAQ1-treated PAR4mKO mice (n=3). (A-C) TEG parameters: R time (A), α-angle (B) and MA (C). (D) Representative TEG traces. Data shown as mean ± SD. Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparison test. Symbols directly over bars represent significance compared to control. **P< .01, ****P < .0001.